Stella Pharma Corporation

4888

JP3399680002

Pharmaceuticals

Delayed Japan Exchange Other stock markets 07:00:00 16/05/2024 BST			5-day change	1st Jan Change
350 ^JPY	+1.74%		+14.75%	+22.81%

02-13	Stella Pharma Corporation Provides Earnings Guidance for the Fiscal Year Ending March 2024	CI
2023	Stella Pharma Corporation Provides Earnings Guidance for the Fiscal Year Ending March 2024	CI

Stella Pharma Corporation announced that it has received funding from SMBC Nikko Securities Inc.

December 29, 2022

On December 30, 2022, Stella Pharma Corporation closed the transaction.

Latest news about Stella Pharma Corporation

Stella Pharma Corporation Provides Earnings Guidance for the Fiscal Year Ending March 2024	02-13	CI
Stella Pharma Corporation Provides Earnings Guidance for the Fiscal Year Ending March 2024	08/08/23	CI
Stella Pharma Corporation Provides Earnings Guidance for the Fiscal Year Ending March 2024	09/05/23	CI
Stella Pharma Corporation Provides Earnings Guidance for the Full Year Ending March 31, 2023	10/02/23	CI
Stella Pharma Corporation announced that it has received funding from SMBC Nikko Securities Inc.	29/12/22	CI
Stella Pharma Corporation announced that it expects to receive funding from SMBC Nikko Securities Inc.	13/12/22	CI
Stella Pharma Corporation Provides Earnings Guidance for the Year Ending March 31, 2023	09/11/22	CI
Mizuho Securities Co., Ltd. acquired unknown minority stake in Stella Pharma Corporation from INCJ, Ltd.	31/10/22	CI
Certain Common Stock of Stella Pharma Corporation are subject to a Lock-Up Agreement Ending on 18-OCT-2021.	17/10/21	CI
Certain Common Stock of Stella Pharma Corporation are subject to a Lock-Up Agreement Ending on 20-JUL-2021.	19/07/21	CI
Stella Pharma Corporation has completed an IPO in the amount of ¥3.400044 billion.	21/04/21	CI
Stella Pharma Corporation has filed an IPO in the amount of ¥3.769614 billion.	19/03/21	CI
Stella Pharma Corporation announced that it has received ¥3.6 billion in funding from Sumitomo Heavy Industries, Ltd., Innovation Network Corporation of Japan	24/03/16	CI
Stella Pharma Corporation announced that it expects to receive ¥3.6 billion in funding from Sumitomo Heavy Industries, Ltd., Innovation Network Corporation of Japan	23/03/16	CI

Chart Stella Pharma Corporation

Duration

Period

More charts

Stella Pharma Corp is a Japan-based company mainly engaged in the therapeutic drug research and development. It is engaged in the research and development of boron drugs for boron neutron capture therapy (BNCT). BNCT is a radiation therapy that selectively destroys cancer cells by utilizing the fission reaction of B-10, which is a stable isotope of boron, and thermal neutrons with low energy. Nucleus of B-10, which is a stable isotope of boron, absorbs low-energy low-speed neutrons and immediately splits into a helium nucleus (4He nucleus (Î± particle)) and a lithium nuclei (7Li nuclei). When a substance containing B-10 selectively accumulates in cancer cells and is irradiated with thermal neutrons, cancer cells are selectively destroyed. Product includes steboronin (SPM-011). A phase II clinical trial is conducted for brain tumor, head and neck cancer and recurrent malignant glioma. Phase I clinical trial is started for malignant melanoma, a type of skin cancer, and angiosarcoma.

Sector

Pharmaceuticals

Calendar

06/08/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
STELLA PHARMA CORPORATION	+22.81%	69.38M
ELI LILLY AND COMPANY	+32.36%	709B
NOVO NORDISK A/S	+30.77%	595B
JOHNSON & JOHNSON	-1.60%	367B
MERCK & CO., INC.	+20.07%	334B
ABBVIE INC.	+6.04%	289B
ASTRAZENECA PLC	+14.77%	239B
NOVARTIS AG	+9.13%	211B
ROCHE HOLDING AG	-3.97%	203B
AMGEN INC.	+9.27%	171B